AstraZeneca Reports final analysis Data for Atezolizumab in Hairy cell leukemia

AstraZeneca today announced final analysis results for Atezolizumab in patients with Hairy cell leukemia. The study demonstrated that Atezolizumab achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Hairy cell leukemia and support the continued development of Atezolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Atezolizumab was consistent with previous observations, with no new safety signals identified.